FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167170024> ?p ?o ?g. }

• W2167170024 endingPage "262" @default.
• W2167170024 startingPage "251" @default.
• W2167170024 abstract "Background:Multiple sclerosis (MS) is a chronic inflammatory disease, affecting more than 2.5 million people worldwide with more 400,000 cases in the United States alone. There has been considerable improvement in the treatment of MS, with the introduction of disease-modifying drugs; however, new oral therapies may provide additional benefit by providing an alternative treatment modality and the potential for improved adherence by avoiding the injection-associated side effects and anxiety encountered with some first-line agents. BG-12 (dimethyl fumarate) is an oral agent approved in the United States for the treatment of relapsing forms of MS.Scope:We review published literature about what is known about the mechanism of action of BG-12, and key efficacy and safety findings from three clinical studies in patients with relapsing-remitting MS (RRMS).Findings:Data from preclinical studies have demonstrated that BG-12 may promote anti-inflammatory and cytoprotective activities that are mediated, at least in part, by the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway. Studies in animals have shown a protective effect of BG-12 on neuronal, axonal and myelin integrity. Results from a phase 2 study and two randomized double-blind placebo-controlled phase 3 studies, CONFIRM and DEFINE, have shown that BG-12 provides clinical and radiologic efficacy in patients with RRMS. At 2 years, BG-12 240 mg twice and three times daily reduced annualized relapse rate (CONFIRM primary endpoint) by 44% and 51% and the risk of relapse (DEFINE primary endpoint) by 49% and 50%, respectively, compared with placebo (all p < 0.001). BG-12 was generally well tolerated and had an acceptable safety profile, with a similar incidence of adverse events across treatment groups.Conclusions:BG-12 may have cytoprotective and anti-inflammatory properties that contribute to its efficacy among patients with RRMS. Findings from phase 2 and 3 studies further support BG-12 as an effective initial therapy.ClinicalTrials.gov ID:NCT00168701; NCT00420212: NCT00451451." @default.
• W2167170024 created "2016-06-24" @default.
• W2167170024 creator A5029734617 @default.
• W2167170024 creator A5032922361 @default.
• W2167170024 creator A5052565461 @default.
• W2167170024 creator A5067317369 @default.
• W2167170024 creator A5070874554 @default.
• W2167170024 creator A5075052252 @default.
• W2167170024 creator A5077638926 @default.
• W2167170024 creator A5081217869 @default.
• W2167170024 creator A5083755468 @default.
• W2167170024 creator A5086627945 @default.
• W2167170024 date "2013-10-22" @default.
• W2167170024 modified "2023-10-16" @default.
• W2167170024 title "BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety" @default.
• W2167170024 cites W1967253329 @default.
• W2167170024 cites W1967838438 @default.
• W2167170024 cites W1968195247 @default.
• W2167170024 cites W1970046036 @default.
• W2167170024 cites W1970068928 @default.
• W2167170024 cites W1978094617 @default.
• W2167170024 cites W1986173197 @default.
• W2167170024 cites W1991631628 @default.
• W2167170024 cites W2003265473 @default.
• W2167170024 cites W2004815940 @default.
• W2167170024 cites W2005506388 @default.
• W2167170024 cites W2009679952 @default.
• W2167170024 cites W2015243552 @default.
• W2167170024 cites W2015734871 @default.
• W2167170024 cites W2017750827 @default.
• W2167170024 cites W2022905263 @default.
• W2167170024 cites W2033175786 @default.
• W2167170024 cites W2033274952 @default.
• W2167170024 cites W2043591841 @default.
• W2167170024 cites W2056473837 @default.
• W2167170024 cites W2061806673 @default.
• W2167170024 cites W2062102383 @default.
• W2167170024 cites W2067396516 @default.
• W2167170024 cites W2072439629 @default.
• W2167170024 cites W2072718666 @default.
• W2167170024 cites W2073788442 @default.
• W2167170024 cites W2076889715 @default.
• W2167170024 cites W2086815472 @default.
• W2167170024 cites W2093009907 @default.
• W2167170024 cites W2094026727 @default.
• W2167170024 cites W2096000363 @default.
• W2167170024 cites W2097593378 @default.
• W2167170024 cites W2103294049 @default.
• W2167170024 cites W2104948944 @default.
• W2167170024 cites W2112165124 @default.
• W2167170024 cites W2114459506 @default.
• W2167170024 cites W2124417387 @default.
• W2167170024 cites W2125719936 @default.
• W2167170024 cites W2130698201 @default.
• W2167170024 cites W2130779793 @default.
• W2167170024 cites W2136687695 @default.
• W2167170024 cites W2139367012 @default.
• W2167170024 cites W2145657433 @default.
• W2167170024 cites W2146883699 @default.
• W2167170024 cites W2151340435 @default.
• W2167170024 cites W2152100400 @default.
• W2167170024 cites W2160413407 @default.
• W2167170024 cites W2167582118 @default.
• W2167170024 cites W2168198006 @default.
• W2167170024 cites W2188468660 @default.
• W2167170024 cites W2325038063 @default.
• W2167170024 cites W2331134705 @default.
• W2167170024 cites W2334914692 @default.
• W2167170024 cites W2509277703 @default.
• W2167170024 cites W2916040650 @default.
• W2167170024 doi "https://doi.org/10.1185/03007995.2013.849236" @default.
• W2167170024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24131282" @default.
• W2167170024 hasPublicationYear "2013" @default.
• W2167170024 type Work @default.
• W2167170024 sameAs 2167170024 @default.
• W2167170024 citedByCount "95" @default.
• W2167170024 countsByYear W21671700242014 @default.
• W2167170024 countsByYear W21671700242015 @default.
• W2167170024 countsByYear W21671700242016 @default.
• W2167170024 countsByYear W21671700242017 @default.
• W2167170024 countsByYear W21671700242018 @default.
• W2167170024 countsByYear W21671700242019 @default.
• W2167170024 countsByYear W21671700242020 @default.
• W2167170024 countsByYear W21671700242021 @default.
• W2167170024 countsByYear W21671700242022 @default.
• W2167170024 countsByYear W21671700242023 @default.
• W2167170024 crossrefType "journal-article" @default.
• W2167170024 hasAuthorship W2167170024A5029734617 @default.
• W2167170024 hasAuthorship W2167170024A5032922361 @default.
• W2167170024 hasAuthorship W2167170024A5052565461 @default.
• W2167170024 hasAuthorship W2167170024A5067317369 @default.
• W2167170024 hasAuthorship W2167170024A5070874554 @default.
• W2167170024 hasAuthorship W2167170024A5075052252 @default.
• W2167170024 hasAuthorship W2167170024A5077638926 @default.
• W2167170024 hasAuthorship W2167170024A5081217869 @default.
• W2167170024 hasAuthorship W2167170024A5083755468 @default.
• W2167170024 hasAuthorship W2167170024A5086627945 @default.
• W2167170024 hasConcept C126322002 @default.

• next